SynthesisCardiovascular research2018
Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.
Synthesis in Cardiovascular research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis.European journal of clinical pharmacology · 2021Pooled it
- Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.Circulation. Genomic and precision medicine · 2022Trial
- Beyond Cholesterol Lowering: Clinical Caution, Personalization, and Nutritional Integration in Statin Therapy.Nutrients · 2026Review
- Genetic Biomarkers for Statin-Induced Myopathy.International journal of molecular sciences · 2025Article
- Dietary Modulation of CYP3A4 and Its Impact on Statins and Antidiabetic Drugs: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Association of Coenzyme Q10 Supplementation With Statin-Associated Muscle Symptoms in Long-Term Statin Users.Cureus · 2025Article
- Effects of Vitamin D, Infliximab, and Leflunomide on Isolated Rat Striated Muscle with Electrical and Mechanical Stimuli in Statin-Induced Rhabdomyopathy.Journal of clinical practice and research · 2025Article
- Article
- Article
- QPGx-CARES: Qatar pharmacogenetics clinical applications and research enhancement strategies.Clinical and translational science · 2024Review
- Muscular toxicity of colchicine combined with statins: a real-world study based on the FDA adverse event reporting system database from 2004-2023.Frontiers in pharmacology · 2024Article
- The Role of Environmental Factors in the Development of Idiopathic Inflammatory Myopathies: a Narrative Review.Current rheumatology reports · 2023Review
- Adverse drug reactions of statin therapy in China from 1989 to 2019: a national database analysis.European journal of hospital pharmacy : science and practice · 2023Article
- Predictive Value ofGenes · 2023Article
- Pharmacotherapy of the Lipid-Lowering Drugs: Update on Efficacy and Risk.International journal of molecular sciences · 2023Article
- [Rhabdomyolysis due to drug-drug interaction of atorvastatin and cobicistat].Innere Medizin (Heidelberg, Germany) · 2022Article
- Statins Neuromuscular Adverse Effects.International journal of molecular sciences · 2022Review
- A Cost-Consequence Analysis of PreemptiveJournal of personalized medicine · 2021Article
- Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy.International journal of molecular sciences · 2021Review
- [Diagnostics and treatment of statin-associated muscle symptoms].Der Internist · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Statin therapy reduces cardiovascular events in patients with, or at risk of, atherosclerotic cardiovascular disease. However, statins are underutilized in patients for whom they are indicated and are frequently discontinued. Discontinuation may be the result of statin-associated muscle symptoms (SAMS), which encompass a broad spectrum of clinical phenotypes from myalgia to severe myopathy. As with many adverse drug reactions (ADRs), inter-individual variability in susceptibility to SAMS is due, at least in part, to differences in host genetics. The genetic basis for SAMS has been investigated in candidate gene studies, genome-wide association studies, and, more recently, studies of multi-omic networks, including at the transcriptome level. In this article, we provide a systematic review of the pharmacogenetic basis of SAMS, focusing on how an understanding of the genetic and molecular determinants of SAMS can be considered in a personalized approach to reduce the incidence of this ADR, optimize statin adherence, and reduce the risk for cardiovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.